NLCR in Prediction of the Grade of Lung Tumor.

November 20, 2018 updated by: Piotr Palaczyński, Medical University of Silesia

Preoperative Neutrophil-lymphocyte Count Ratio in Prediction of the Grade of Lung Tumor.

The aim of the study is to assess whether the value of neutrophil-lymphocyte count ratio from the routine preoperative blood test may predict lung tumors' grading.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Lung cancer remains as one of the leading causes of death among oncology patients. Close connection between inflammation and pathogenesis of some neoplasms was determined in a number of studies. Some studies show promise that ratio of neutrophil to lymphocyte count (NLCR) may be recognized as a prognostic marker for several carcinomas: renal, lung and colorectal. The aim of the study is to assess whether the value of neutrophil-lymphocyte count ratio from the routine preoperative blood test may predict lung tumors' grading. During routine preoperative blood tests complete blood count is done and NLCR, WBC, neutrophil and lymphocyte count is noted. After the thoracic surgery intervention and histopathological examination grading of lung tumor is noted.

Study Type

Observational

Enrollment (Actual)

400

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Poland
    • Silesia
      • Zabrze, Silesia, Poland, 41-800
        • Samodzielny Publiczny Szpital Kliniczny Nr 1

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Consecutive thoracic surgery patients admitted to SPSK nr 1 in Zabrze between October 2014 and October 2018 with lung tumor qualified for thoracic surgery intervention

Description

Inclusion Criteria:

  • consecutive thoracic surgery patients with lung cancer grading confirmed by histopathology postoperatively
  • preoperative routine complete blood count analysis

Exclusion Criteria:

  • infectious disease
  • pregnancy
  • autoimmunologic disease
  • other known conditions or treatments that may influence the blood count (seropositivity for HIV, chemotherapy, and corticotherapy)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Observational Group
Group of patients with lung tumor qualified for thoracic surgery intervention with routine, preoperative complete blood count test and routine postoperative histopathological examination of lung tumor.
Diagnostic test: Complete blood count
During routine preoperative blood test complete blood count is taken.
Other: Histopathological examination
Routine postoperative histopathological examination of lung tumor.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Neutrophil-lymphocyte count ratio
Time Frame: From October 1, 2014 to October 15, 2018
Neutrophil-lymphocyte count ratio is measured during routine preoperative blood tests.
From October 1, 2014 to October 15, 2018

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Neutrophil count
Time Frame: From October 1, 2014 to October 15, 2018
Neutrophil count is measured during routine preoperative blood tests.
From October 1, 2014 to October 15, 2018
Lymphocyte count
Time Frame: From October 1, 2014 to October 15, 2018
Lymphocyte count is measured during routine preoperative blood tests.
From October 1, 2014 to October 15, 2018
Leucocyte count
Time Frame: From October 1, 2014 to October 15, 2018
Leucocyte count is measured during routine preoperative blood tests.
From October 1, 2014 to October 15, 2018

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Medical University of Silesia

Investigators

  • Study Chair: Hanna Misiołek, MD PhD, Medical University of Silesia

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 1, 2014

Primary Completion (Actual)

October 15, 2018

Study Completion (Actual)

November 16, 2018

Study Registration Dates

First Submitted

November 16, 2018

First Submitted That Met QC Criteria

November 20, 2018

First Posted (Actual)

November 21, 2018

Study Record Updates

Last Update Posted (Actual)

November 21, 2018

Last Update Submitted That Met QC Criteria

November 20, 2018

Last Verified

November 1, 2018

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • NLCR-01

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Lung Neoplasm

Clinical Trials on Complete blood count

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Moldova

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe